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Abstract
The  authors  report  a  novel,  alternative
approach to treat malignant peritoneal mesothe-
lioma  (MPeM)  targeting,  vascular  endothelial
growth  factor  (VEGF)  using  anti-VEGF  (beva-
cizumab) chemotherapy combination. 
Case Report
In June 2008, a 60-year-old Jordanian man
presented with abdominal distension and para
umbilical hernia. His medical history was sig-
nificant for hypertension, diabetes mellitus and
hyperlipidemia and the patient was receiving
regular treatment. The patient underwent her-
nia repair and the hernia sac sent for histo  -
pathologic examination. Histopathologic find-
ings  showed  atypical  mesothelial  cells  with
prominent nucleoli and occasional mieotic fig-
ures as well as areas of focal necrosis, psammo-
matous  calcification  and  tumor  cells  showed
encroachment on the adipose tissue illustrated
by microscopic appearance (resolution 200X)
of the tumor showing papillary structures on
one side and sheets of malignant tumor on the
other  side,  as  shown  in  Figure  1.  Immuno-
peroxidase  stain  for  mesothelioma  markers
was positive for calretinin, AE1, AE3, HBME-1,
cytokeratin 5/6 (CK 5/6), FMA, and negative for
Vimentin, CEA, CD15 and Ber-FP4 providing a
conclusive diagnosis of MPeM.
Figure  2  shows  microscopic  appearance
(resolution 200X) of positive immunostaining
of  neoplastic  cells  by  HRP  conjugated
Cytokeratin 5/6 antibody. Cytological examina-
tion of ascitic fluid showed mesothelial cells
with features of malignancy, CEA was 2.3 IU/L,
AFP was 9.4 IU/L. Complete blood picture, renal
and liver function tests were normal. CT scan
of chest and abdomen showed gross ascites,
multiple  mediastinal  and  abdominal  lymph
nodes enlargement, diffused nodular mass in
the omentum and peritoneal lining central and
right  side  of  the  abdomen,  as  revealed  in
Figure 3 CT scan image taken in October 2008
showing peritoneum  thickening and ascites.
The  patient  was  treated  with  cisplatin  75
mg/m
2 + pemetrexed 500 mg/m
2 i.v every three
weeks after draining about 10 liters of ascitic
fluid. Although repeated CT scan showed some
resolution of the enlarged lymph nodes, omen-
tal and peritoneal nodes, the patient required
aspiration of nearly 6-8 liters of ascitic fluid
with each cycle. With other chemotherapy reg-
imens  including  gemcitabine  +  pemetrexed
for 2 cycles and intraperitoneal cisplatin the
patient continued to have re-accumulation of
the ascitic fluid.
In  January  2009  the  patient  started  with
combination of gemcitabine 1250 mg/m
2 plus
bevacizumab  5  mg/kg  every  2  weeks.  The
patient responded clinically with no require-
ment of aspiration from the very first cycle of
treatment and received 6 cycles of treatment
providing strong evidence of clinical response
and improvement in quality of life. Side effects
like epistaxis were observed which was mild
and managed by local pressure.
MPeM is a cancer of extremely rare occur-
rence and arises from the mesothelial cells of
the peritoneum. It accounts for only 10% of all
mesotheliomas  with  majority  arising  from
pleura and the role of asbestos exposure in the
etiology compared to pleural mesothelioma is
not well defined.
1,2 The clinical manifestations
of  this  disease  are  usually  abdominal  pain,
increasing  abdominal  girth,  weight  loss  and
abdominal  masses  with  or  without  ascites.
Though it can occur in any age group, the most
affected is the 50 to 69 year age group.
2,3 The
aggressive  nature  of  the  disease  is  evident
with rapid spread within the confines of the
abdominal  cavity  involving  most  accessible
peritoneal and omental surfaces and requires
aggressive treatment. Mortality and morbidity
are associated with the spread of the disease
rather than the metastasis and without aggres-
sive treatment the neoplasm is rapidly fatal.
2,4,5
Studies  that  have  reported  patients  with
peritoneal  mesothelioma  are  few  and  treat-
ment of MPeM have largely extrapolated from
the treatment of pleural disease.
6 Currently, no
standard treatment for this disease has been
established  and  management  involves  an
intensive  loco-regional  treatment  strategy
including cytoreductive surgery, intraoperative
and/or  perioperative  intraperitoneal  chemo-
therapy  using  doxorubicin,  cisplatin,  and
interferon gamma with or without abdominal
radiation and cytoreductive surgery along with
hyperthermic  intraperitoneal  chemotherapy
using  mitomycin  and  cisplatin  followed  by
whole  body  irradiation.
1,5 Several  studies
demonstrated  an  improved  overall  survival
with  these  regimes  as  compared  to  historic
controls, treated with systemic chemotherapy
and  palliative  surgery  in  which  the  median
survival  was  uniformly  less  than  1  year.
4
However,  extensive  intraperitoneal  disease
precludes the possibility of cytoreductive sur-
gery always and these multimodality therapeu-
tic strategies are associated with significant
morbidity.
1
A  number  of  chemotherapeutic  agents
either  single  or  in  combination  with  other
drugs have shown promise in the treatment of
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Figure 1. Micro-scopic appearance of the
tumor showing papillary structures on one
side and sheets of mali-gnant tumor on the
other side.
Figure 2. Positive immunostaining of neo-
plastic cells by HRP conjugated cytoker-
atin 5/6 antibody (resolution 200X).[Rare Tumors 2009; 1:e49] [page 151]
MPeM. Nevertheless, the low incidence of the
disease  and  clinical  heterogeneity  precludes
Phase II efforts to define conclusively the ben-
efit of systemic chemotherapy and other treat-
ment options. The Expanded Access Program
(EAP) conducted both in the US and interna-
tionally provided access to 109 patients with
MPeM  including  chemo-naive  or  previously
treated patients with MPeM not amenable to
curative surgery. This study showed that medi-
an survival for pemetrexed (antifolates) was
10.3  months,  and  1-year  survival  rates  for
pemetrexed  with  cisplatin  and  pemetrexed
alone  were  57.4%  (95%  CI:  10.3,  100)  and
41.5% (95% CI 4.6, 78.4), respectively. The dis-
ease control rate was 71.2% in MPeM patients,
establishing the value of this treatment regime
in improving survival in patients with unre-
sectable MPeM.
6-8
For patients who cannot tolerate a platinum-
based regimen a Phase II trial (20 patients)
provided  an  alternative  regimen  with  gemc-
itabine  and  pemetrexed  documenting  a  dis-
ease control rate (DCR) of 50%, median TTPD
(time to progressive disease) and OS of 10.4
months and 26.8 months, respectively.
1
In  addition,  a  Phase  III  trial  where  456
patients was assigned randomly to cisplatin 75
mg/m
2 alone  or  with  pemetrexed  500  mg/m
2
indicated that supplementation with folic acid
and vitamin B12 resulted in improved survival
time, TTPD, response rates and significantly
reduced treatment related toxicity when com-
pared to non-supplemented patients.
7
VEGF plays key role in MPeM biology and in
a  Phase  II  trial  anti  VEGF  antibody  (beva-
cizumab 15 mg/kg) was added to gemcitabine
1250 mg/m
2 plus cisplatin 75 mg/m
2 regimen,
improvement  in  overall  survival  with  beva-
cizumab combination was not demonstrated in
this study.
9
This patient presented with abdominal dis-
tension,  which  is  a  presenting  symptom  in
majority  of  cases.  CT  scan  findings  of
mesothelioma are nonspecific but are useful
for detection, characterization and staging. It
is also useful for guiding biopsy of peritoneal
masses. Definitive diagnosis is based on histo-
logical  and  immunohistochemical  examina-
tion.
Cytologic  sampling  of  ascitic  fluid  and
Immunohistochemical  expression  of  tumor
markers (calretinin and cytokeratin 5/6) pro-
vides a diagnosis of MPeM in approximately
80% of the cases. Since pemetrexed in combi-
nation with cisplatin showed survival improve-
ments, the patient started with this regime.
Failure to show clinical response as evidenced
by repeated aspirations of 6-8 liters, the treat-
ment was changed to gemcitabine plus peme-
trexed and cisplatin was not included in the
regime  as  the  patient  failed  to  respond  to
intraperitoneal  cisplatin.  The  constant  non-
response of the patient to this regime, led to
Case Report
Figure 3. CT scan in October 2008 showed peritoneal thickening and ascites.
Figure 4. CT scan in July 2009 showed resolution of the peritoneal thickening and
hydronephrosis of right kidney.[page 152] [Rare Tumors 2009; 1:e49]
change in treatment and the patient was con-
tinued  to  be  treated  with  bevacizumab  and
gemcitabine  due  to  a  strong  evidence  of
improvement in clinical response and quality
of life. This was observed by no requirement of
aspiration of ascitic fluid until August 2009 (7
months post treatment) and the patient was
working  and  maintained  his  job  during  this
period. Figure 4 showed CT scan image taken
in  July  2009  showed  resolution  of  the  peri-
toneal thickening as depicted in the anterior
and hydronephrosis of the right kidney at the
posterior. This case demonstrates that beva-
cizumab in combination chemotherapy could
be  an  effective  alternative  treatment  in
patients  who  are  non-responsive  to  other
proven agents and highlights the need for fur-
ther  clinical  studies  to  establish  the  role  of
bevacizumab  in  the  treatment  of  MPeM  to
improve progression free survival and overall
survival. 
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